VolitionRx Limited Announces Exercise of Over-Allotment Option in Previously Announced Public Offering
NAMUR, Belgium, Feb. 17, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that the underwriters of its previously announced offering of common stock have exercised the option to purchase an additional 343,383 shares at a price of $3.75 per share.
National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (OTCBB: NHLD) and Lake Street Capital Markets acted as joint book running managers for the offering. The Benchmark Company acted as co-manager for the offering.
A registration statement on Form S-1 relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective on February 5, 2015. Copies of the prospectus relating to the offering may be obtained by request to the offices of National Securities Corporation, Attn: Kim Addarich, Senior Vice President, 410 Park Avenue, 14th Floor, New York, NY 10022, Email: [email protected]; or the offices of Lake Street Capital Markets, LLC, Attn: Equity Syndicate Department, 225 South 6th St, Ste 2050, Minneapolis, MN 55402, Telephone: (888) 330-4648, Email: [email protected]; or the on the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale is not permitted.
About VolitionRx
VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Visit VolitionRx's website (www.volitionrx.com) or connect with us via Twitter, LinkedIn or Facebook.
Media Contacts
Charlotte Reynolds, VolitionRx
[email protected]
Telephone: +44 (0) 795 217 7498
Kirsten Thomas, The Ruth Group
[email protected]
Telephone: +1 (646) 536-7014
Investor Contacts
Scott Powell, Investor Relations
[email protected]
Telephone: +1 (646) 650-1351
Lee Roth, The Ruth Group
[email protected]
Telephone: +1 (646) 536-7012
SOURCE VolitionRX Ltd
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article